Sandoz International GmbH
www.sandoz.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sandoz International GmbH
Sandoz Lines Up Higher-Strength Adalimumab In Europe
Sandoz is looking to enter the European market for high-concentration adalimumab after announcing EMA acceptance of its filing for a 100mg/ml version of its Hyrimoz biosimilar. Celltrion and Stada/Alvotech already have higher-strength rivals to Humira available in Europe.
Sandoz Launches Global Biosimilars Initiative
Sandoz has launched a global campaign to increase uptake of biosimilars, under the banner of Act4Biosimilars. The initiative aims to increase the adoption of biosimilars by at least 30% in at least 30 countries by 2030.
BMS Plans Appeal After Sandoz And Teva Eliminate UK Eliquis Patent
While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.
Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars
Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs